

Catalog	Unit
TBI3035-50MG	50 mg
TBI3035-250MG	250 mg

### Product Details

**Formal Name:** 2-Cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl) ester

**Alternate Names:** FR34235

**Molecular Formula:** C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>O<sub>6</sub>

**Formula Weight:** 385.38

**CAS Number:** 75530-68-6


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml).

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Syk inhibitor & Ca<sup>2+</sup> channel blocker

### Functions

A novel DHP L-type Ca<sup>2+</sup> channel blocker that also inhibits Syk. Blocks A $\beta$  production, APP $\beta$  secretion and reduces BACE-1 expression in CHO cells over-expressing A $\beta$  in vitro. Enhances clearance of A $\beta$  across the blood brain barrier in vivo. Reduces brain A $\beta$  levels in a mouse tauopathy model. Clinically useful antihypertensive agent. Has been shown to prevent cognitive decline in some clinical trials. Produces a protective effect on glutamate neurotoxicity in retinal ganglion cells, an effect not shared by other L-type Ca<sup>2+</sup> channel blockers such as nifedipine and diltiazem.

### Application Procedures

First dissolved in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

**For research use only.**